Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clinicians. 2021;71(3):209–249.

Article  Google Scholar 

Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol. 2016;22(1):7–17.

Article  PubMed  PubMed Central  Google Scholar 

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.

Article  PubMed  Google Scholar 

Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of Hepatocellular Carcinoma: A Review. JAMA Surg. 2023;158(4):410–420.

Article  PubMed  Google Scholar 

Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362.

Article  CAS  PubMed  Google Scholar 

Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36.

Article  CAS  PubMed  Google Scholar 

Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681–693.

Article  PubMed  Google Scholar 

Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11(9):525–35.

Article  CAS  PubMed  Google Scholar 

Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380.

Article  PubMed  Google Scholar 

European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.

Article  Google Scholar 

Aslam A, Chernyak V, Miller FH, et al. CT/MRI LI-RADS 2024 Update: Treatment Response Assessment. Radiology. 2024;313(2):e232408.

Article  PubMed  Google Scholar 

Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018;289(3):816–830.

Jin YJ, Chung YH, Kim JA, et al. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization. Dig Dis Sci. 2013;58(6):1758–1765.

Article  CAS  PubMed  Google Scholar 

Jeong SO, Kim EB, Jeong SW, et al. Predictive factors for complete response and recurrence after transarterial chemoembolization in hepatocellular carcinoma. Gut Liver. 2017;11(3):409–416.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Young S, Sanghvi T, Sharma S, et al. Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma. Diagn Interv Imaging. 2022;103(3):143–149.

Article  PubMed  Google Scholar 

Farid K, Elalfy H, Abo El-Khair SM, et al. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. Expert Rev Gastroenterol Hepatol. 2020;14(12):1203–1214.

Article  CAS  PubMed  Google Scholar 

Liu HF, Xu YS, Liu Z, et al. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization. Acad Radiol. 2021;28(6):790–798.

Article  PubMed  Google Scholar 

Zhu HD, Li X, Sun JH, et al. Transarterial chemoembolization with epirubicin-loaded microspheres for hepatocellular carcinoma: A prospective, single-arm, multicenter, phase 2 study (STOPPER Trial). Cardiovasc Intervent Radiol. 2024;47(3):325–336.

Article  PubMed  PubMed Central  Google Scholar 

Milot L. Hepatocellular carcinoma assessment after locoregional treatment: A primer on LI-RADS contrast-enhanced nonradiation treatment response assessment version 2024. Radiology. 2024;311(2):e240124.

Article  PubMed  Google Scholar 

Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307(2):e221835.

Article  PubMed  Google Scholar 

Wei H, Yang T, Chen J, Duan T, Jiang H, Song B. Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions. Liver Int. 2022;42(10):2131–2144.

Article  CAS  PubMed  Google Scholar 

Jiang H, Wei J, Fu F, et al. Predicting microvascular invasion in hepatocellular carcinoma: A dual-institution study on gadoxetate disodium-enhanced MRI. Liver Int. 2022;42(5):1158–1172.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee S, Kim SH, Lee JE, Sinn DH, Park CK. Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. J Hepatol. 2017;67(3):526–534.

Article  CAS  PubMed  Google Scholar 

Renzulli M, Brocchi S, Cucchetti A, et al. Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology. 2016;279(2):432–442.

Article  PubMed  Google Scholar 

Gluskin JS, Chegai F, Monti S, Squillaci E, Mannelli L. Hepatocellular carcinoma and diffusion-weighted MRI: Detection and evaluation of treatment response. J Cancer. 2016;7(11):1565–1570.

Article  PubMed  PubMed Central  Google Scholar 

Park MS, Kim S, Patel J, et al. Hepatocellular carcinoma: detection with diffusion-weighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients. Hepatology. 2012;56(1):140–148.

Article  PubMed  Google Scholar 

Ilagan CH, Goldman DA, Gönen M, et al. Recurrence of hepatocellular carcinoma after complete radiologic response to trans-arterial embolization: A retrospective study on patterns, treatments, and prognoses. Ann Surg Oncol. 2022;29(11):6815–6826.

Article  PubMed  PubMed Central  Google Scholar 

Cho SM, Chu HH, Kim JW, Kim JH, Gwon DI. Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20–40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm. Life (Basel). 2021;11(4):358.

PubMed  Google Scholar 

Saito N, Nishiofuku H, Sato T, et al. Predictive Factors of Complete Response to Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma beyond Up-To-7 Criteria. Cancers (Basel). 2023;15(9):2609.

Article  PubMed  Google Scholar 

Xing F, Ma Q, Lu J, et al. Nodule-in-nodule architecture of hepatocellular carcinomas: enhancement patterns in the hepatobiliary phase and pathological features. Abdom Radiol (NY). 2024 Jun 24. Epub ahead of print.

Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36.

Article  CAS  PubMed  Google Scholar 

Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang B, Liang J, Qu Z, Yang F, Liao Z, Gou H. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review. PLoS One. 2020;15(2):e0227475.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bargellini I, Lorenzoni V, Lorenzoni G, et al. Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis. Eur Radiol. 2021;31(10):7512–7522.

Article  CAS  PubMed  PubMed Central  Google Scholar